scholarly journals Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial

HIV Medicine ◽  
2015 ◽  
Vol 17 (7) ◽  
pp. 505-515 ◽  
Author(s):  
E Wilkins ◽  
M Fisher ◽  
AJ Brogan ◽  
SE Talbird ◽  
EM La
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Treatment Naïve ◽  
Aids Clinical Trials ◽  
The Uk ◽  
Hiv 1

scholarly journals PGI8 COST-EFFECTIVENESS ANALYSIS OF ROTAVIRUS VACCINATION PROGRAMME IN THE UK

2006 ◽  
Vol 9 (6) ◽  
pp. A243-A244 ◽  
Author(s):  
N Largeron ◽  
M Trichard ◽  
H Miadi-Fargier ◽  
A Trancard ◽  
A D'Ausilio ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Vaccination Programme ◽  
Cost Effectiveness Analysis ◽  
Rotavirus Vaccination ◽  
Effectiveness Analysis ◽  
The Uk

scholarly journals Choice of Fluids in Severe Septic Patients - A Cost-effectiveness Analysis Informed by Recent Clinical Trials

2014 ◽  
Vol 9 (1) ◽  
pp. 21-30 ◽  
Author(s):  
Albert Farrugia ◽  
Megha Bansal ◽  
Sonia Balboni ◽  
Mary Kimber ◽  
Gregory Martin ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 419-419
Author(s):  
Ali Raza Khaki ◽  
Yong Shan ◽  
Richard Nelson ◽  
Sapna Kaul ◽  
John L. Gore ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cost Effectiveness ◽  
Incremental Cost ◽  
Randomized Clinical Trials ◽  
Pathologic Complete Response ◽  
Weighted Average ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Sensitivity Analyses ◽  
Effectiveness Analysis

419 Background: Multiple single-arm clinical trials have shown promising pathologic complete response (pCR) rates with neoadjuvant ICIs in MIBC. However, ICIs remain costly. We conducted a cost-effectiveness analysis comparing neoadjuvant ICIs with CBC. Methods: We applied a decision analytic simulation model with a health care payer perspective and two-year time horizon to compare neoadjuvant ICIs vs CBC. For the primary analysis we compared pembrolizumab with dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC). We performed a secondary analysis with gemcitabine/cisplatin (GC) as CBC and exploratory analyses with atezolizumab or nivolumab/ipilimumab as ICIs (vs both ddMVAC and GC). We input pCR rates from trials (ICIs) or a weighted average of prior studies (CBC) and costs from average sales price. Outcomes of interest included costs, 2-year recurrence-free survival (RFS), and incremental cost-effectiveness ratio (ICER) of cost per 2-year RFS. A threshold analysis estimated a pCR rate or price reduction for ICI to be cost-effective and one-way and probabilistic sensitivity analyses were performed. Results: Results of the cost effectiveness analysis are shown in the table. The incremental cost of pembrolizumab compared with ddMVAC was $8,042 resulting in an incremental improvement of 0.66% in 2-year RFS for an ICER of $1,218,485 per 2-year RFS. A pCR of 71% or a 26% reduction in cost of pembrolizumab would render it more cost-effective with an ICER of $100,000 per 2-year RFS. GC required a 96% pembrolizumab cost reduction to achieve an ICER of $100,000 per 2-year RFS. Atezolizumab appeared to be more cost-effective than ddMVAC, even though the 2yr RFS was 0.66% worse. Conclusions: ICIs were not cost-effective as neoadjuvant therapies, except when atezolizumab was compared with ddMVAC. Pembrolizumab would approach cost-effective thresholds with 26% or 96% reduction in cost when compared to ddMVAC and GC, respectively. Randomized clinical trials, larger sample sizes and longer follow-up are required to better understand the value of ICIs as neoadjuvant treatments. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document